Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine.

Autor: Vreman S; Wageningen Bioveterinary Research, Wageningen University & Research, the Netherlands; Cell Biology & Immunology group, Wageningen University & Research, the Netherlands. Electronic address: Sandra.vreman@wur.nl., McCaffrey J; Xeolas, Pharmaceuticals, Dublin, Ireland., Popma-de Graaf DJ; Wageningen Bioveterinary Research, Wageningen University & Research, the Netherlands., Nauwynck H; Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium., Savelkoul HFJ; Cell Biology & Immunology group, Wageningen University & Research, the Netherlands., Moore A; School of Pharmacy, School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland., Rebel JMJ; Wageningen Livestock Research, Wageningen University & Research, the Netherlands., Stockhofe-Zurwieden N; Wageningen Bioveterinary Research, Wageningen University & Research, the Netherlands.
Jazyk: angličtina
Zdroj: Veterinary immunology and immunopathology [Vet Immunol Immunopathol] 2019 Jun; Vol. 212, pp. 27-37. Date of Electronic Publication: 2019 Apr 30.
DOI: 10.1016/j.vetimm.2019.04.008
Abstrakt: Toll-like receptor (TLR) agonists can effectively stimulate antigen-presenting cells (APCs) and are anticipated to be promising adjuvants in combination with inactivated vaccines. In this study, the adjuvant potential of three different TLR-agonists were compared with an oil-in-water (O/W) adjuvant in combination with inactivated porcine reproductive and respiratory syndrome virus (iPRRSV) applied by different administration routes: intramuscular (i.m.) or into the skin using dissolving microneedle (DMN) patches. Pigs received a prime vaccination followed by a booster vaccination four weeks later. TLR1/2 (Pam3Cys), TLR7/8 (R848) or TLR9 (CpG ODN) agonists were used as adjuvant in combination with iPRRSV strain 07V063. O/W adjuvant (Montanide™) was used as reference control adjuvant and one group received a placebo vaccination containing diluent only. All animals received a homologous challenge with PRRSV three weeks after the booster vaccination. Antibody and IFN-γ production, serum cytokines and viremia were measured at several time-points after vaccination and/or challenge, and lung pathology at necropsy. Our results indicate that a TLR 1/2, 7/8 or 9 agonist as adjuvant with iPRRSV does not induce a detectable PRRSV-specific immune response, independent of the administration route. However, the i.m. TLR9 agonist group showed reduction of viremia upon challenge compared to the non-vaccinated animals, supported by a non-antigen-specific IFN-γ level after booster vaccination and an anamnestic antibody response after challenge. Montanide™-adjuvanted iPRRSV induced antigen-specific immunity after booster combined with reduction of vireamia. Skin application of TLR7/8 agonist, but not the other agonists, induced a local skin reaction. Further research is needed to explore the potential of TLR agonists as adjuvants for inactivated porcine vaccines with a preference for TLR9 agonists.
(Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: